Abcam tests every one of its RabMAb primary antibodies via flow cytometry, Western blot, IHC, ICC/IF and IP analysis in several different species (Human, Rat, Mouse) prior to them being made available.
RabMAb primary antibodies are advantageous as they utilize diverse epitope recognition that results from the unique immune development of rabbits. This ability, when combined with the high specificity that monoclonal antibodies afford, provides excellent results in many different applications.
- For immunohistochemistry each RabMAb primary antibody is verified on a formalin-fixed and paraffin-embedded (FFPE) human tissue array – resulting in a more accurate determination of antibody localization and sensitivity.
- Each RabMAb product is recommended to be applied three times
Validation Results for Caspase-3 (Pro) RabMAb Primary Antibody (ab32150)
Validation data for Caspase-3 (Pro) RabMAb primary antibody (ab32150) on:
A) WB on HeLa cell lysate
B) IHC on FFPE human cervical carcinoma tissue
C) Flow Cyt on Jurkat cells
D) ICC on HeLa cells.
Validation Results for AKT1 RabMAb® Primary Antibody (ab32505)
Validation data for AKT1 RabMAb® primary antibody (ab32505) on:
A) WB on MCF-7 cell lysate
B) IHC on FFPE human prostate carcinoma tissue
C) Flow Cyt on MCF-7 cells
D) ICC on MCF-7 cells. (PubMed)
Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.